Harbin Pharmaceutical Group Co., Ltd. (600664.SS)
- Previous Close
2.8300 - Open
2.9000 - Bid 3.0000 x --
- Ask 3.0100 x --
- Day's Range
2.8900 - 3.0400 - 52 Week Range
2.4100 - 3.9000 - Volume
81,524,141 - Avg. Volume
33,634,736 - Market Cap (intraday)
7.589B - Beta (5Y Monthly) --
- PE Ratio (TTM)
18.81 - EPS (TTM)
0.1600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date May 4, 2018
- 1y Target Est
--
Harbin Pharmaceutical Group Co., Ltd. engages in the research, development, manufacture, and trading of pharmaceuticals in China and internationally. The company offers pharmaceutical products for blood and hematopoietic, antineoplastic and immunomodulatory, respiratory, anti-inflammatory and analgesic, and chronic diseases, as well as mineral supplements, Chinese medicines, and antibiotics. It offers its products under the Harbin Pharmaceutical, Sanjing, Gaizhonggai, Hutong, and Shiyitang brands. The company is based in Harbin, China.
www.hayao.com9,853
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 600664.SS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 600664.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 600664.SS
Valuation Measures
Market Cap
7.14B
Enterprise Value
5.94B
Trailing P/E
17.69
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.45
Price/Book (mrq)
1.51
Enterprise Value/Revenue
0.38
Enterprise Value/EBITDA
5.87
Financial Highlights
Profitability and Income Statement
Profit Margin
2.87%
Return on Assets (ttm)
3.01%
Return on Equity (ttm)
9.80%
Revenue (ttm)
15.67B
Net Income Avi to Common (ttm)
449.71M
Diluted EPS (ttm)
0.1600
Balance Sheet and Cash Flow
Total Cash (mrq)
2.85B
Total Debt/Equity (mrq)
35.64%
Levered Free Cash Flow (ttm)
439.92M
Research Analysis: 600664.SS
Company Insights: 600664.SS
600664.SS does not have Company Insights